drugset / Trial / NCT04339140
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
Phase 2
Completed
5 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. * The name of the study drug involved in this study is: * Zafirlukast
Timeline
- Start
- 2020-06-24
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zafirlukast | Small molecule | — | Oral |